Drug Trial Radar · NCT00002772
S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jan 24, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
602
Actual
Start
Jul 1996
Primary completion
Feb 2004
Study completion Feb 2004
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Cancer and Leukemia Group B
- First posted
- Apr 22, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which regimen of chemotherapy followed by peripheral stem cell transplantation is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating women who have undergone surgery for breast cancer.
Conditions
- Breast Cancer
Interventions
filgrastimBiological
carboplatinDrug
carmustineDrug
cisplatinDrug
cyclophosphamideDrug
doxorubicin hydrochlorideDrug
paclitaxelDrug
tamoxifen citrateDrug
thiotepaDrug
autologous bone marrow transplantationProcedure
peripheral blood stem cell transplantationProcedure
radiation therapyRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Memorial Sloan-Kettering Cancer Center
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.